41,620 Shares in KalVista Pharmaceuticals, Inc. $KALV Purchased by SG Americas Securities LLC

SG Americas Securities LLC purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 41,620 shares of the specialty pharmaceutical company’s stock, valued at approximately $507,000. SG Americas Securities LLC owned approximately 0.08% of KalVista Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Emerald Advisers LLC increased its position in shares of KalVista Pharmaceuticals by 15.6% during the second quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock valued at $11,735,000 after purchasing an additional 139,859 shares during the period. Ameriprise Financial Inc. boosted its stake in KalVista Pharmaceuticals by 2,258.6% during the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares in the last quarter. Geode Capital Management LLC increased its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company’s stock valued at $10,642,000 after buying an additional 25,971 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in shares of KalVista Pharmaceuticals by 26.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after buying an additional 160,759 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of KalVista Pharmaceuticals by 19.0% during the 2nd quarter. Bank of America Corp DE now owns 366,966 shares of the specialty pharmaceutical company’s stock worth $4,149,000 after acquiring an additional 58,719 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Needham & Company LLC upped their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. HC Wainwright upped their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Finally, TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Insider Buying and Selling

In other news, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $71,231.20. Following the sale, the insider directly owned 131,831 shares of the company’s stock, valued at $1,773,126.95. This represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brian Piekos sold 4,471 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the sale, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. This represents a 29.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 31,329 shares of company stock worth $437,371 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Stock Down 3.1%

NASDAQ KALV opened at $16.02 on Friday. The firm has a market cap of $809.81 million, a PE ratio of -4.06 and a beta of -0.14. KalVista Pharmaceuticals, Inc. has a one year low of $8.49 and a one year high of $19.00. The stock’s 50 day simple moving average is $15.33 and its 200 day simple moving average is $13.83. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.04. The business had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million. As a group, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.